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Abstract
Background: Increasing the knowledge about heart failure (HF) costs and their determinants is important to
ascertain how HF management can be optimized, leading to a significant decrease of HF costs. This study
evaluated the cumulative costs and healthcare utilisation in HF patients in Spain.
Methods: Observational, retrospective, population-based study using BIG-PAC database, which included data from
specialized and primary care of people ≥18 years, from seven autonomous communities in Spain, who received
care for HF between 2015 and 2019. The healthcare and medication costs were summarized on a yearly basis
starting from the index date (1st January 2015), and then cumulatively until 2019.
Results: We identified 17,163 patients with HF (year 2015: mean age 77.3 ± 11.8 years, 53.5% men, 51.7% systolic HF,
43.6% on NYHA functional class II). During the 2015–2019 period, total HF associated costs reached 15,373 Euros
per person, being cardiovascular disease hospitalizations the most important determinant (75.8%), particularly HF
hospitalizations (51.0%). Total medication cost accounted for 7.0% of the total cost. During this period, there was a
progressive decrease of cardiovascular disease hospital costs per year (from 2834 Euros in 2015 to 2146 Euros in
2019, P < 0.001), as well as cardiovascular and diabetic medication costs.
Conclusions: During the 2015–2019 period, costs of HF patients in Spain were substantial, being HF
hospitalizations the most important determinant. Medication costs represented only a small proportion of total
costs. Improving HF management, particularly through the use of drugs that reduce HF hospitalization may be
helpful to reduce HF burden.
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Background
Heart Failure (HF) is a complex clinical syndrome caused
by structural or functional cardiac alterations, leading to a
reduced cardiac output or elevated intracardiac pressures
at rest or during stress, that cause the typical symptoms
such as breathlessness, or fatigue [1, 2]. HF is a growing
problem worldwide [3]. It has been estimated that the
prevalence of HF is around 2% of the adult population in
developed countries, raising to more than 10% in those
individuals aged 70 years or older [4]. In Spain, it has been
reported a higher prevalence of HF, reaching 5% in some
studies [5, 6]. Of note, it is expected that the prevalence of
HF will increase in the following years, mainly due to the
ageing of the population, the rise in HF risk factors (i.e.
hypertension, diabetes) and the better treatment of acute
cardiovascular events [3].
Despite traditional HF therapies (i.e renin angiotensin
system inhibitors, beta blockers and aldosterone antago-
nists), mortality and hospitalization rates remain un-
acceptably high [7, 8]. Thus, the MAGGIC meta-analysis
that included individual data on 39,372 patients with
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HF, from 30 cohort studies showed that 40.2% of pa-
tients died after 2.5 years of follow-up [8]. However, in
the last years, the PARADIGM-HF and more recently,
the DAPA-HF trials have shown that sacubitril/valsartan
and dapagliflozin, respectively, have a positive impact on
morbidity and mortality among patients with HF and re-
duced left ventricular ejection fraction [9, 10].
Remarkably, HF represents a major and growing eco-
nomic problem [3, 11, 12]. Studies particularly focused
on HF economic burden are important as they contrib-
ute to a better understanding of the drivers and prob-
lems which may lead to the increasing HF costs [3].
Increasing the knowledge about HF costs and their de-
terminants is important in order to ascertain how HF
management can be optimized, leading to a significant
decrease of HF costs [3, 7, 11, 12]. Unfortunately, data
about costs of HF in Spain are very scarce or limited to
the use of specific drugs, but not focused on a compre-
hensive approach [13–18]. For example, a study per-
formed in Spain in 2014 among only 374 patients
reported a high total cost associated with HF [18]. As a
result, new studies with a high number of patients that
provide current data are warranted.
The aim of this study was to evaluate the cumulative
costs and healthcare utilisation in HF patients in Spain
over the last 5 years, along with the epidemiological
characterization of the population at index date (1st
January 2015). This was also analyzed in a population
who met the most relevant inclusion criteria of the
DAPA-HF trial [10] (DAPA-HF like population) with
the aim of understanding the costs associated with the
management of HF with reduced ejection fraction from
the DAPA-HF trial population.
Methods
Observational cohort study, comprising cross-sectional
and longitudinal retrospective analyses using secondary
data captured in electronic health records from seven
Spanish regions. Data sources were provided by BIG-
PAC®. BIG-PAC is an electronic database that integrate
information from primary and specialist care medical re-
cords. This database has been validated as an informa-
tion source for studies of epidemiology, therapeutic
adaptation and health/non-healthcare resource use and
associated costs. It is representative of the Spanish popu-
lation [19].
The HF population was defined as all patients ≥18
years of age and with at least one diagnosis of HF prior
to the index date (first January 2015). Type 2 diabetes
(T2D) was defined as all patients ≥18 years of age filling
a prescription of any antidiabetic medication, T2D diag-
nosis or HbA1c > 7% prior to index date. The DAPA-HF
like population included those patients ≥18 years, with a
HF history of more than 8 weeks, treatment with device
therapy or standard HF treatment, NYHA class ≥II
within 1 year prior to index date and left ventricular
ejection fraction ≤40%. Patients with HF hospitalization
in the previous 4 weeks prior to index date, myocardial
infarction, unstable angina pectoris, stroke, transient is-
chemic attack, coronary revascularization or implant-
ation of therapeutic device < 12 weeks prior to index
date, were excluded from the population.
Comorbidities were searched for in all available data
prior to index date, excepting for severe hypoglycemia
that was considered only within 1 year before index date
and cancer which was searched for up to 5-year prior to
index date. A minimum of 1 year of data before index
date was required. Comorbidities included cardiovascu-
lar disease (myocardial infarction, percutaneous or surgi-
cal revascularization, unstable angina, angina pectoris),
HF, chronic kidney disease, atrial fibrillation, stroke
(hemorrhagic, ischemic, transitory ischemic attack), per-
ipheral artery disease, major organ specific bleeding,
microvascular complications (diabetic mono−/polyneur-
opathy, diabetic eye complications, diabetic kidney dis-
ease), severe hypoglycemia, cancer, chronic obstructive
pulmonary disease, and lower limb complications. ICD-9
and ICD-10 codes (https://eciemaps.mscbs.gob.es) were
considered for the diagnosis of comorbidities (supple-
mentary Table 1).
The information about treatment was recorded from
the registries for dispensing medicines, according to the
Anatomical Therapeutic Chemical Classification System
(supplementary Table 1) [20]. HF treatments (angioten-
sin-converting enzyme inhibitors, angiotensin receptor
blockers, beta blockers, aldosterone antagonists, sacubi-
tril/valsartan, loop diuretics, digoxin), warfarin, statins, as-
pirin, receptor P2Y12 antagonists, calcium channel
blockers, thiazides, nitrates, antidiabetic medications
(SGLT-2 inhibitors, metformin, sulfonylurea, DPP-4 in-
hibitors, GLP-1 receptor agonists, metiglinides, glitazones,
acarbose, miglitol, insulin) were recorded. The prescrip-
tion of a drug in a specific patient was based only on med-
ical criteria (clinical practice).
Prevalence, incidence and baseline characteristics
(total HF population and by T2D status), including
demographics, comorbidities and medications were cal-
culated at index date (first January 2015).
The healthcare resource use and costs and medication
costs were summarized for the total HF population on a
yearly basis starting from index date (first January 2015),
and then cumulatively until the end of the last year of
follow up (31st December 2019). All hospital visits (total
and cardiovascular events), the number of medical visits
and emergency room visits and medication costs (total,
cardiovascular related, HF related and diabetes related)
were included for the analysis of the annual direct
healthcare costs. Patients who died during follow-up had
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a cost of 0 allocated to the remaining duration of the
study, whereas a patient leaving the database prior to
data cut off was not included in the denominator for the
time after leaving the database. Annual indirect non-
health costs included the number of days of productivity
lost due to disability.
Rates were obtained from hospital accounting, except
for the medication and indirect costs which were calcu-
lated as follows, respectively: a) medical prescriptions:
according to the retail price per package at the time of
dispensing [21]; b) costs for days of productivity lost: ac-
cording to the mean interprofessional wage [22]. Hos-
pital admission costs for cardiovascular events during
follow-up were obtained taking into consideration daily
hospital rate and number of hospital days per stay. Rates
are summarized in supplementary Table 2.
Statistical analysis
Categorical variables were described by their absolute
(n) and relative frequencies (%). Continuous variables
were described using the mean and standard deviation.
Categorical variables were compared with the Chi-
square test or the Fisher exact test when appropriate.
When two means were compared, the t-student test was
used. Analyses of health care cost were performed for
the index date with 5 year of follow-up. The cumulative
mean healthcare cost was estimated and presented on a
yearly basis from the index date until last year of follow-
up. Health care costs were presented per patient (mean
cost). A level of statistical significance of 0.05 was ap-
plied in all the statistical tests. The data were analyzed
using the statistical package SPSS v22.0 (SPSS Inc., Chi-
cago, Illinois, USA).
Results
Out of 1,7 millions of persons included in the BIG-PAC®
database in 2015, 1,3 million people were attended dur-
ing the 2012–2014 period, of whom 964,862 were 18
years or older. At index date, 17,598 patients had HF. As
435 patients were excluded due to inconsistent data, 17,
163 patients (1.78%) comprised the HF study population
(Fig. 1). Incidence at index date was 2.84 × 1000 patient-
years.
The baseline clinical characteristics of the HF popula-
tion according to the presence of T2D were presented in
Table 1. Overall, mean age was 77.3 ± 11.8 years, 53.5%
of patients were men, 51.7% of patients had reduced left
ventricular ejection fraction HF, and the majority of pa-
tients were on NYHA functional class II (43.6%) or III
(36.1%). A total of 5815 (33.9%) patients had T2D. The
presence of other comorbidities was common: 30.0% of
patients had atrial fibrillation, 29.5% chronic kidney dis-
ease, 23.3% ischemic heart disease, 17.2% chronic ob-
structive pulmonary disease, 12.8% cancer and 9.5%
previous stroke. Two thirds of patients were taking renin
angiotensin system inhibitors, 68.3% beta blockers,
30.0% aldosterone antagonists, and 8.5% sacubitril/val-
sartan. The baseline clinical profile of patients according
to the presence of T2D was also compared. The percent-
age of patients with left ventricular ejection fraction
≤40% was higher in patients with type 2 diabetes (53.1%
vs 51.0%; P = 0.015). Those patients with T2Dd had
more ischemic heart disease, stroke, atrial fibrillation,
peripheral artery disease, and chronic kidney disease,
and a higher body mass index (P < 0.05 or less for all
comorbidities).
Patient hospital mean cost for year was presented in
Table 2. In general, from 2015 to 2019, there was a pro-
gressive decrease of cardiovascular disease hospital cost
per patient year (from 2834 to 2146 Euros, P < 0.001).
Overall, patient cumulative cardiovascular disease
Fig. 1 Flowchart cost population (2015)
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Table 1 Baseline clinical characteristics of the heart failure population at index date 1st January 2015 according to the presence of
type 2 diabetes
No T2D (n = 11,348; 66.1%) T2D
(n = 5815; 33.9%)
Total HF
(n = 17,163; 100%)
P*
Biodemographic data
Age, years 77.4 ± 12.6 77.2 ± 10.1 77.3 ± 11.8 0.236
≥ 85 years, n (%) 6308 (55.6) 2648 (45.5) 8956 (52.2) < 0.001
Gender, male, n (%) 6052 (53.3) 3135 (53.9) 9187 (53.5) 0,470
Body mass index, Kg/m2 28.1 (5.8) 29.5 (6.0) 28.6 (5.9) < 0.001
Systolic blood pressure (mmHg) 128.7 ± 21.9 131.8 ± 22.6 129.8 ± 22.2 < 0,001
Heart failure data
NYHA functional class, n (%)
I 1321 (11,6) 654 (11.3) 1975 (11.5)
II 5008 (44.1) 2476 (42.6) 7484 (43.6) 0.001
III 4068 (35.9) 2135 (36.7) 6203 (36.1)
IV 395 (3.5) 268 (4.6) 663 (3.9)
Left ventricular ejection fraction, % 44.2 ± 10.6 41.5 ± 12.4 43.3 ± 11.3 < 0.001
≤ 40%, n (%) 5217 (51.0) 2798 (53.1) 8015 (51.7) 0.012
> 40 - < 50%, n (%) 801 (7.8) 428 (8.1) 1229 (7.9) 0.012
≥ 50%, n (%) 4217 (41.2) 2039 (38.7) 6256 (40.4) 0.012
Laboratory data
eGFR, ml/min/1.73m2 76.1 ± 20.4 72.3 ± 20.4 74.8 ± 20.5 < 0.001
HbA1c, % 5.2 ± 0.9 7.3 ± 0.8 6.1 ± 1.4 < 0.001
Comorbidities
Cardiovascular disease, n (%)
Ischemic heart disease 2174 (19.1) 1834 (31.5) 4006 (23.3) < 0.001
Myocardial infarction 1350 (11.9) 1126 (19.4) 2466 (14.4) < 0.001
CABG 122 (1.1) 132 (2.3) 254 (1.5) 0.001
PCI with stent 285 (2.5) 243 (4.2) 528 (3.1) < 0.001
Unstable angina 414 (3.7) 384 (6.6) 798 (4.7) < 0.001
Angina pectoris 686 (6.1) 493 (8.5) 1179 (6.9) < 0.001
Stroke 1015 (8.9) 622 (10.7) 1637 (9.5) < 0.001
Ischemic stroke 779 (6.9) 467 (8.0) 1246 (7.3) 0.005
Hemorrhagic stroke 72 (0.6) 28 (0.5) 100 (0.6) 0.213
Transitory ischemic attack 256 (2.3) 173 (3.0) 429 (2.5) 0.004
Atrial Fibrillation 3339 (29.4) 1805 (31.0) 5144 (30.0) 0.029
Peripheral artery disease 500 (4.4) 326 (5.6) 826 (4.8) 0.001
Chronic kidney disease 2819 (24.8) 2236 (38.5) 5055 (29.5) < 0.001
Microvascular complications 0 1810 (31.1) 1810 (10.5) < 0.001
Diabetic mono−/polyneuropathy 0 380 (6.5) 380 (2.2) < 0.001
Diabetic eye complications 0 1598 (27.5) 1849 (10.8) < 0.001
Diabetic foot/peripheral angiopathy 0 251 (4.3) 264 (1.5) < 0.001
Diabetic kidney disease 0 468 (8.1) 521 (3.0) < 0.001
Diabetes with complications 0 3207 (55.2) 3452 (20.1) < 0.001
Severe hypoglycemia 0 461 (7.9) 461 (2.7) < 0.001
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hospital mean cost reached 11,649 Euros in 2019 (sup-
plementary Table 3 and Fig. 2). The great burden for
this cost was due to cardiorenal (HF and/or chronic kid-
ney disease) hospitalizations (88.8% of the total cost),
particularly HF (67.3% of the total cost). With regard to
medication, from 2015 to 2019, diabetes medication
mean cost varied from 101 to 85 Euros (P < 0.001) per
patient and year and HF medication mean cost from 86
to 90 Euros (P < 0.001), respectively (Table 2). The cu-
mulative mean cost of diabetes medication and HF
medication reached 486 and 417 Euros, respectively, in
2019 (supplementary Table 3 and Fig. 3).
Table 1 Baseline clinical characteristics of the heart failure population at index date 1st January 2015 according to the presence of
type 2 diabetes (Continued)
No T2D (n = 11,348; 66.1%) T2D
(n = 5815; 33.9%)
Total HF
(n = 17,163; 100%)
P*
Other comorbidities, n (%)
Cancer 1465 (12.9) 733 (12.6) 2198 (12.8) 0.572
Chronic obstructive pulmonary disease 1928 (17.0) 1027 (17.7) 2955 (17.2) 0.270
Lower limb amputations 37 (0.3) 108 (1.9) 145 (0.8) < 0.001
Major organ specific bleeding 111 (1.0) 177 (3.0) 288 (1.7) < 0.001
Therapies
Heart failure medications, n (%) 11,348 (100) 5815 (100) 17,163 (100) –
Renin angiotensin system inhibitors 6973 (61.5) 4452 (76.6) 11,425 (66.6) < 0.001
Angiotensin-converting enzyme inhibitors 3354 (29.6) 1986 (34.2) 5340 (31.1) < 0.001
Angiotensin receptor blockers 3619 (31.9) 2466 (42.4) 6085 (35.5) < 0.001
Beta blockers 7509 (66.2) 4218 (72.5) 11,727 (68.3) < 0.001
Loop-diuretics 7416 (65.4) 4645 (79.9) 12,061 (70.3) < 0.001
Aldosterone antagonists 3424 (30.2) 1728 (29.7) 5152 (30.0) 0.537
Sacubitril/valsartan 987 (8.7) 477 (8.2) 1464 (8.5) 0.272
Digoxin 799 (7.0) 398 (6.8) 1197 (7.0) 0.632
Other cardiovascular medications, n (%)
Low dose aspirin 3017 (26.6) 2037 (35.0) 5054 (29.5) < 0.001
Receptor P2Y12 antagonists 1177 (10.4) 634 (10.9) 1811 (10.6) 0.284
Statins 5928 (52.2) 3238 (55.7) 9166 (53.4) < 0.001
Antihypertensives 2415 (21.3) 1478 (25.4) 3893 (22.7) < 0.001
Dihydropyridines CCB 1564 (13.8) 1027 (17.7) 2591 (15.1) < 0.001
Thiazides 520 (4,6) 268 (4,6) 788 (4.6) 0,938
Non-hydropyridines CCB 504 (4,4) 290 (5,0) 794 (4.6) 0,107
Nitrates 1169 (10,3) 788 (13,6) 1957 (11,4) < 0,001
Warfarin 2438 (21,5) 1464 (25,2) 3902 (22,7) < 0,001
Diabetes medications, n (%) 0 5383 (92.6) 5383 (31.4) < 0.001
Metformin 0 3862 (66.4) 3862 (22.5) < 0.001
Sulfonylurea 0 1952 (33.6) 1952 (11.4) < 0.001
DPP4 inhibitors 0 1416 (24.4) 1416 (8.3) < 0.001
SGLT-2 inhibitors 1 (0%) 2 (0) 3 (0) < 0.001
GLP-1 receptor agonists 0 57 (1.0) 57 (0.3) < 0.001
Metiglinides 0 319 (5.5) 319 (1.9) < 0.001
Glitazones 0 57 (1.0) 57 (0.3) < 0.001
Acarbose 0 88 (1.5) 88 (0.5) < 0.001
Insulin 0 1367 (23.5) 1367 (8.0) < 0.001
T2D Type 2 diabetes, HF Heart failure, eGFR Estimated glomerular filtration rate, CABG Coronary artery bypass graft, PCI Percutaneous coronary intervention, CCB
Calcium channel blockers, DPP4 Dipeptidyl peptidase 4, SGLT-2 Sodium-glucose Cotransporter-2, GLP-1 Glucagon-like peptide-1
*p values comparing no T2D vs T2D
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The health resources use for each year, including pri-
mary care visits, specialized visits, emergency rooms
visits, hospitalization and diagnostic tests, was shown in
Table 3. The proportion of hospitalized patients de-
creased from 31.5% in 2015 to 22.9% in 2019 (P < 0.001),
the days for hospitalized patients due to HF from 8.3 to
7.2 days (P < 0.001), and the proportion of patients that
died from 9.4 to 4.9% (P < 0.001), respectively. Total
sanitary cost decreased from 3700 Euros in 2015 to 2770
Euros in 2019 (P < 0.001). Including indirect costs, total cu-
mulative patient mean costs reached 15,373 Euros in 2019,
263,852,978 Euros per total HF population (Table 4).
A specific analysis was performed in the DAPA-HF
like population (n = 3178). In this subpopulation, mean
age was 76.9 ± 11.7 years, 51.4% were men, and all pa-
tients had reduced left ventricular ejection fraction HF
Table 2 Patients hospital mean cost for yeara
2015 2016 2017 2018 2019 Cumulative
cost in
2019
mean SD mean SD mean SD mean SD mean SD
Total hospital cost
CVD 2834 5212 2416 5065 2268 4839 1985 4937 2146 4947 11,649
Cardiorenal 2536 4859 2155 4565 2001 4433 1759 4329 1896 4460 10,346
HF 1967 4094 1657 3814 1476 3609 1297 3505 1447 3604 7842
CKD 569 2173 498 2024 525 2057 463 1943 450 1968 2504
MI 98 812 87 800 79 760 70 776 83 761 416
Stroke 138 970 126 942 132 977 108 940 113 887 616
PAD 63 740 49 619 57 682 48 660 54 602 271
Medication cost
Total medication 230 425 216 426 227 426 204 432 206 421 1083
Diabetes medication 101 336 97 336 118 324 85 308 85 317 486
HF medication 86 130 79 131 76 203 86 268 90 313 417
CVD medication 44 96 40 91 33 80 33 86 31 339 181
CVD Cardiovascular disease, HF Heart failure, CKD Chronic kidney disease, cardiorenal HF and/or CKD, MI Myocardial infarction, PAD Peripheral artery disease
aIn Euros
Fig. 2 Patient cumulative hospital mean cost*. *In Euros. CVD: cardiovascular disease; HF: heart failure; CKD: chronic kidney disease; cardiorenal:
HF and/or CKD; MI: myocardial infarction; PAD: peripheral artery disease
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Fig. 3 Patient cumulative medication mean cost*. *In Euros. CVD: cardiovascular disease; HF: heart failure
Table 3 Health resources use for each year per patient
2015 2016 2017 2018 2019
mean SD mean SD mean SD mean SD mean SD
Primary care visits, mean (SD) 12.7 15.0 10.9 14.2 9.6 13.9 8.8 14.3 7.7 13.0
Laboratory requests, mean (SD) 0.6 1.2 0.6 1.2 0.6 1.2 0.7 1.6 1.0 2.1
Radiology and other tests, mean (SD) 0.6 1.2 0.6 1.2 0.6 1.2 0.7 1.6 1.0 2.2
Specialized visits, mean (SD) 2.1 4.2 1.3 4.9 1.1 4.8 1.2 4.9 1.1 4.8
Emergency rooms visits, mean (SD) 0.8 2.5 0.7 3.3 0.7 3.1 0.5 2.3 0.5 3.3
Hospitalization
Days, mean (SD) 5.9 10.8 5.0 10.5 4.7 10.0 4.1 10.3 4.5 10.3
Hospitalized patients, n (%) 5399 (31.5) 4557 (26.6) 4227 (24.6) 3628 (21.1) 3923 (22.9)
Days for hospitalized patients due to heart failure only, mean (SD) 8.3 10.7 7.7 10.6 7.5 10.1 6.9 10.1 7.2 10.2
Frequency of hospitalization, n (%)
0 11,764 (68.5) 12,606 (73.5) 12,936 (75.4) 13,535 (78.9) 13,240 (77.1)
1 4243 (24.7) 3565 (20.8) 3225 (18.8) 2780 (16.2) 2914 (17.0)
2 1001 (5.8) 855 (5.0) 867 (5.1) 724 (4.2) 850 (5.0)
3+ 156 (0.9) 137 (0.8) 137 (0.8) 124 (0.7) 160 (0.9)
Disability
Days of disability, mean (SD) 0.4 5.9 0.4 6.0 0.6 10.9 0.4 5.7 0.4 5.1
Patients with disability, n (%) 158 (0.9) 132 (0.8) 134 (0.8) 140 (0.8) 190 (1.1)
Average days of sick leave (disability only), mean (SD) 43.8 43.5 47.4 49.5 77.2 96.9 50.5 38.5 36.7 32.6
Mortality, n (%) 1608 (9.4) 1259 (7.3) 927 (5.4) 893 (5.2) 839 (4.9)
All years calculated with 17.163 patients
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(mean left ventricular ejection fraction 34.5 ± 7.9%). The
majority of patients were on NYHA functional class II
(52.1%) or III (43.0%). A total of 1314 (41.3%) patients
had T2D. With regard HF medication, 77.0% of patients
were taking renin angiotensin system inhibitors, 100%
beta blockers, 21.0% aldosterone antagonists, and 8.8%
sacubitril/valsartan. Compared with patients without
diabetes, those patients with T2D were taking more
renin angiotensin system inhibitors, aldosterone antago-
nists and sacubitril/valsartan (supplementary Table 4).
With regard to patients hospital mean cost for year for
this subpopulation, there was a progressive decrease of
cardiovascular disease hospital cost per year (from
3269.6 Euros in 2015 to 2539.5 Euros in 2019, P <
0.001). Overall, patient cumulative cardiovascular disease
hospital mean cost reached 13,775 Euros in 2019. The
great burden for this cost was due to cardiorenal hospi-
talizations (87.7% of the total hospital cost), particularly
HF (65.9% of the total hospital cost). With regard to
medication, from 2015 to 2019, diabetes medication
mean cost decreased from 128.5 to 74.6 Euros (P <
0.001) and HF medication mean cost from 112.9 to 74.7
Euros (P < 0.001), respectively. The cumulative mean cost
of diabetes medication and HF medication reached 540 and
514 Euros, respectively, in 2019 (supplementary Table 5).
Discussion
Our study showed that in Spain, during the 2015–2019
period HF associated costs were high (patient total cost of
15,373 Euros), being cardiovascular hospitalizations the most
important determinant (75.8%), particularly HF hospitaliza-
tions (51.0%). Total medication cost accounted for 7% of the
total HF cost. In addition, the annual cardiovascular
hospitalization mean cost progressive decreased over time.
In our study, the prevalence of HF was about 1.8%.
With regards to the HF population, mean age was 77
years, around half of patients had systolic HF, the
majority of patients were on NYHA functional class II
or III, one third had diabetes and comorbidities were
common. In Spain, the studies performed in different
clinical settings (hospital and outpatients) show a higher
prevalence of HF [23]. However, the population-based
studies reported similar numbers to our study [24]. The
proportion of patients with systolic HF, as well as the
presence of numerous comorbidities are in line with pre-
vious studies [5, 24]. As a result, our study can be con-
sidered fairly representative of the Spanish population.
With regards to HF therapies, approximately two
thirds of patients were taking renin angiotensin system
inhibitors and beta blockers, nearly one third aldoster-
one antagonists, and only 8.5% sacubitril/valsartan. The
optimization of treatment of patients with HF is neces-
sary not only to improve functional class and quality of
life, but also to reduce morbidity and mortality [1, 2].
These numbers are lower than those reported in HF
units, but in line with those from other clinical settings
[25, 26]. This is very relevant, as the underuse of
evidence-based HF medication is associated with a
higher use of healthcare resources, particularly first and
recurrent hospitalizations [27].
During the period 2015–2019, patient cumulative car-
diovascular disease hospital mean cost reached 11,649
Euros. Importantly, cardiorenal hospitalizations were the
most important contributor for the total cost, particu-
larly HF hospitalizations. Overall, HF hospitalizations
represent 1–2% of total admissions [7, 28] and HF is the
most common diagnosis in elderly hospitalized patients
[29]. During the first year after diagnosis of HF, approxi-
mately half of the patients may be expected to be hospi-
talized at least once. In addition, readmission rates are
high [7, 30–32]. Importantly, it has been reported that in
Spain, rates of first hospitalization due to HF continue
to increase, with high mortality [32]. A recent systematic
review analyzed 16 cost-of-illness studies related to HF.
Table 4 Patients total mean cost for year and cumulative cost in 2019a
2015 2016 2017 2018 2019 Cumulative
cost in
2019
mean SD mean SD mean SD mean SD mean SD
Cost of primary care visits 308 362 264 344 231 336 214 345 186 315 1202
Cost of laboratory requests 20 39 19 38 18 37 24 50 32 69 113
Cost of radiology and other tests 24 46 22 45 21 45 28 59 37 80 131
Cost of specialized visits 195 392 123 467 108 451 108 462 101 452 635
Cost of emergency rooms visits 89 291 81 394 79 363 57 276 61 382 368
Cost of Hospitalization 2834 5212 2416 5065 2268 4839 1985 4937 2146 4947 11,649
Cost of medication 230 425 216 426 227 426 204 432 206 421 1083
Sanitary Cost 3700 5623 3141 5516 2920 5347 2620 5153 2770 5181 15,151
Indirect Cost/Sick Leave 41 597 37 606 61 1.104 42 578 41 520 222
Total Cost 3741 5665 3178 5553 2981 5482 2662 5202 2811 1276 15,373
aIn Euros
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Although there were large variations concerning cost
components, the majority of them showed that hospital
admission costs were the most expensive cost element.
Annual costs for HF patients ranged from 868 Dollars
(≈774 Euros) for South Korea to 25,532 Dollars (≈22,760
Euros) for Germany [3]. Other systematic review focused
on economic HF burden also showed that
hospitalization cost was found to be the main cost driver
to the total health care cost and that the HF annual cost
ranged from 908 Dollars (≈809 Euros) to 40,971 Dollars
(≈36,522 Euros) per patient [12]. In our study, during
the 2015–2019 period, HF associated costs per patient
reached 15,373 Euros, in line with these studies. How-
ever, among other factors, methodological heterogeneity
and specific cost items (including treatments) accounted
for in the estimations indicate that cost comparisons
across publications should be made with caution [33].
Certainly, all these data confirm the high cost burden of
HF. Some factors such as age, renal function, blood pres-
sure, NYHA functional class, diabetes, body mass index,
or medication/diet nonadherence have been associated
with a higher morbidity and mortality. Therefore, since
HF hospitalization is the main driver for HF costs, the
early identification of these patients is mandatory, as
these patients require a more careful follow-up and a
greater intensification of treatment, in order to reduce
HF burden [34, 35].
As the most important contributor for HF cost is HF
hospitalizations, the use of those drugs that have demon-
strated to be beneficial in this clinical context may be
very helpful in reducing total HF cost. Thus, in 2014 the
PARADIGM-HF trial showed that compared with enala-
pril, sacubitril/valsartan significantly reduced the risk of
HF hospitalization by 21% and this might have had a
positive impact [9]. In our study, from 2015 to 2019, in
general there was a progressive reduction of cardiovas-
cular disease hospital cost per year, as the proportion of
hospitalized patients decreased. Interestingly, there was
only a slight increase in HF medication cost per year
which is a small contributor for total HF cost. This is in
line with previous studies that have shown a decline in
standardized HF hospitalization rates in Europe and
United States [36, 37]. However, absolute numbers of
HF hospital admissions are expected to increase by
about 50% in the following years due to the ageing of
the population [7]. As a result, new drugs are needed to
improve these numbers. In 2019, the DAPA-HF trial
showed that in addition to recommended therapy, dapa-
gliflozin significantly reduced the risk of a first worsen-
ing HF event by 30% [10]. Therefore, it can be
hypothesized the addition of dapagliflozin to standard
HF therapy may contribute to reduce HF costs.
Other contributors to total HF cost included primary
care visits, specialized visits, and diagnostic tests. It has
been reported that a better integrated hospital primary
care HF program is associated with a significant reduc-
tion of readmission for HF and mortality [38]. In
addition, moving to case management at home rather
than outpatient cardiology clinic follow-up may also re-
duce healthcare costs [39]. Therefore, transition to an
integrated management of HF patients is necessary to
reduce HF burden.
A recent meta-analysis estimated the one, two, five
and 10-year survival to be 87, 73, 57 and 35%, respect-
ively, among HF patients [40]. HF hospitalization is an
independent predictor for increased HF mortality [7, 30,
31]. In our study the proportion of patients who died de-
creased from 9.4% in 2015 to 4.9% in 2019, in line with
the decrease in hospitalization rates. Although there is
much room for progress, it is likely that the improve-
ment in HF management during these years may have
had a positive impact.
A specific analysis was performed in the DAPA-HF
like population. In the DAPA-HF trial, the addition of
dapagliflozin resulted in a significant reduction of HF
hospitalizations, death from cardiovascular causes, and
death from any cause, regardless the presence of dia-
betes [10]. In our study, in the DAPA-HF like popula-
tion, all patients had reduced left ventricular ejection
fraction HF and the majority of patients were on NYHA
functional class II or III. Compared with the overall HF
population, patients were taking more renin angiotensin
system inhibitors and beta blockers. Although in these
patients there was a decrease of patients hospital mean
cost for year, these were higher than in the overall HF
population. Thus, cumulative cardiovascular disease hos-
pital cost reached 13,775 Euros (vs 11,649 Euros in the
overall HF population). The great burden for this cost
was due to cardiorenal hospitalizations (87.7% of the
total hospital cost), particularly HF (65.9% of the total
hospital cost). Therefore, to reduce HF cost burden in
the DAPA-HF like population is of utmost importance
to improve the HF management. As the great majority
of these patients were taking renin angiotensin system
inhibitors and beta blockers, the prescription of newer
HF drugs, such as dapagliflozin, could be of particular
benefit in the reduction of HF costs [10]. In fact, a re-
cent study has shown that dapagliflozin may be a cost-
effective treatment for HF patients in not only in United
Kingdom and Germany, but also Spain [41].
This study has some limitations that should be com-
mented. This was an observational cohort study that
used secondary data from electronic health records. In
addition, there were certain factors, such as some clinical
characteristics that could not be controlled. As a result,
variations in healthcare costs can not only be related
with modifications in the prescription of HF drugs.
Therefore, only indirect causality can be provided.
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However, the high number of patients included, as well
as the robustness of the data may allow to determine the
value of the study. On the other hand, although data
came from seven Spanish regions, previous studies have
shown that these data are representative of the Spanish
population [19].
Conclusion
During the 2015–2019 period, costs of patients with HF
in Spain were high, being cardiovascular hospitalizations
the most important determinant, particularly HF hospi-
talizations. Medication costs were responsible for only a
small proportion of total HF costs. Costs and healthcare
resources use were even higher in the DAPA-HF like
population. Improving HF management, particularly
through the use of those drugs that reduce HF
hospitalization may be helpful to reduce HF burden.
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